BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 26627848)

  • 21. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.
    Talagas M; Uguen A; Garlantezec R; Fournier G; Doucet L; Gobin E; Marcorelles P; Volant A; DE Braekeleer M
    Anticancer Res; 2013 May; 33(5):2065-75. PubMed ID: 23645757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.
    Okamoto S; Nitta M; Maruyama T; Sawada T; Komori T; Okada Y; Muragaki Y
    Brain Tumor Pathol; 2016 Apr; 33(2):129-36. PubMed ID: 26826105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.
    Pajares MJ; Agorreta J; Larrayoz M; Vesin A; Ezponda T; Zudaire I; Torre W; Lozano MD; Brambilla E; Brambilla C; Wistuba II; Behrens C; Timsit JF; Pio R; Field JK; Montuenga LM
    J Clin Oncol; 2012 Apr; 30(10):1129-36. PubMed ID: 22355056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of VEGFR3 in glioma endothelium correlates with tumor grade.
    Grau SJ; Trillsch F; Herms J; Thon N; Nelson PJ; Tonn JC; Goldbrunner R
    J Neurooncol; 2007 Apr; 82(2):141-50. PubMed ID: 17115285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.
    Färkkilä A; Anttonen M; Pociuviene J; Leminen A; Butzow R; Heikinheimo M; Unkila-Kallio L
    Eur J Endocrinol; 2011 Jan; 164(1):115-22. PubMed ID: 21041381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.
    Kwiatkowski SC; Guerrero PA; Hirota S; Chen Z; Morales JE; Aghi M; McCarty JH
    PLoS One; 2017; 12(9):e0185065. PubMed ID: 28938007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab.
    Siegal T; Charbit H; Paldor I; Zelikovitch B; Canello T; Benis A; Wong ML; Morokoff AP; Kaye AH; Lavon I
    J Neurosurg; 2016 Oct; 125(4):1008-1015. PubMed ID: 26799295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas.
    Ludwig HC; Feiz-Erfan I; Bockermann V; Behnke-Mursch J; Schallock K; Markakis E
    Anticancer Res; 2000; 20(1A):299-304. PubMed ID: 10769671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium.
    Punyadeera C; Thijssen VL; Tchaikovski S; Kamps R; Delvoux B; Dunselman GA; de Goeij AF; Griffioen AW; Groothuis PG
    Mol Hum Reprod; 2006 Jun; 12(6):367-75. PubMed ID: 16648151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
    Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
    J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
    Brychtova S; Bezdekova M; Brychta T; Tichy M
    Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intra-amniotic infection upregulates decidual cell vascular endothelial growth factor (VEGF) and neuropilin-1 and -2 expression: implications for infection-related preterm birth.
    Snegovskikh VV; Schatz F; Arcuri F; Toti P; Kayisli UA; Murk W; Guoyang Luo ; Lockwood CJ; Norwitz ER
    Reprod Sci; 2009 Aug; 16(8):767-80. PubMed ID: 19474288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
    Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
    J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
    Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
    Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
    Okita NT; Yamada Y; Takahari D; Hirashima Y; Matsubara J; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
    Jpn J Clin Oncol; 2009 Sep; 39(9):595-600. PubMed ID: 19535387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.
    Keck B; Wach S; Taubert H; Zeiler S; Ott OJ; Kunath F; Hartmann A; Bertz S; Weiss C; Hönscheid P; Schellenburg S; Rödel C; Baretton GB; Sauer R; Fietkau R; Wullich B; Krause FS; Datta K; Muders MH
    Int J Cancer; 2015 Jan; 136(2):443-51. PubMed ID: 24862180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma.
    Straume O; Akslen LA
    Angiogenesis; 2003; 6(4):295-301. PubMed ID: 15166498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.